Raquel Perez-Lopez1,2, Matthew D. Blackledge1,2, Joaquin Mateo1,2, David J. Collins1,2, Veronica A. Morgan1,2, Alison MacDonald1,2, Diletta Bianchini1,2, Zafeiris Zafeiriou1,2, Pasquale Rescigno1,2, Michael Kolinsky1,2, Daniel Nava Rodrigues1,2, Helen Mossop1, Nuria Porta1, Emma Hall1, Martin O. Leach1,2, Johann S. de Bono1,2, Dow-Mu Koh1,2, and Nina Tunariu1,2
We hypothesized that changes in the median apparent diffusion
coefficient (mADC) and volume of bone metastases (BM), quantified by whole body
(WB) diffusion-weighted imaging (DWI), are response biomarkers in metastatic castration-resistant prostate cancer (mCRPC).
21 patients completed WB-DWI at baseline and after 12 weeks of treatment
in a sub-study within a clinical trial of olaparib in mCRPC, performed on a
1.5-T Siemens Avanto scanner. Four different segmentation techniques were explored
including axial skeleton analyses and simpler methods including 5 target
lesions.
Changes in mADC and volume of BM associated with
response to therapy. The simplified approach also showed promising results,
warranting further evaluation.
